$1700 | SAVE $300 | Single User
$3400 | SAVE $600 | Site License
$5100 | SAVE $900 | Enterprise License

Genital Herpes - Pipeline Review, H1 2017
[Report Updated: 22-03-2017]

Published by Global Markets Direct: 22 Mar 2017 | 50184 | In Stock
Related Topics: Healthcare , Infectious Disease

Introduction

Genital Herpes - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Genital Herpes - Pipeline Review, H1 2017, provides an overview of the Genital Herpes (Infectious Disease) pipeline landscape.

Genital herpes is a common sexually transmitted infection that affects both men and women. Genital herpes is caused by the herpes simplex virus (HSV). Symptoms include decreased appetite, fever, general sick feeling (malaise), muscle aches in the lower back, buttocks, thighs, or knees and swollen and tender lymph nodes in the groin during an outbreak. Treatment includes antiviral medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Genital Herpes - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Genital Herpes (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Genital Herpes (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Genital Herpes and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 3, 18 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Genital Herpes (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Genital Herpes (Infectious Disease).

- The pipeline guide reviews pipeline therapeutics for Genital Herpes (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Genital Herpes (Infectious Disease) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Genital Herpes (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Genital Herpes (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Genital Herpes (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Genital Herpes (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
for Genital Herpes - Pipeline Review, H1 2017 [Report Updated: 22-03-2017]

  • Table of Contents

    List of Tables

    List of Figures

    Introduction

    Global Markets Direct Report Coverage

    Genital Herpes - Overview

    Genital Herpes - Therapeutics Development

    Pipeline Overview

    Pipeline by Companies

    Pipeline by Universities/Institutes

    Products under Development by Companies

    Products under Development by Universities/Institutes

    Genital Herpes - Therapeutics Assessment

    Assessment by Target

    Assessment by Mechanism of Action

    Assessment by Route of Administration

    Assessment by Molecule Type

    Genital Herpes - Companies Involved in Therapeutics Development

    Abivax SA

    Admedus Ltd

    AiCuris GmbH & Co KG

    Biomere LLC

    Foamix Pharmaceuticals Ltd

    Genocea Biosciences Inc

    GenVec Inc

    Immune Design Corp

    JN-International Medical Corp

    N & N Pharmaceuticals Inc

    NanoBio Corp

    NanoViricides Inc

    Profectus BioSciences Inc

    Redbiotec AG

    Sanofi Pasteur SA

    Starpharma Holdings Ltd

    Tomegavax Inc

    Vaccibody AS

    Vaxart Inc

    Vical Inc

    Genital Herpes - Drug Profiles

    ABX-196 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    acyclovir - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Aspidasept - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    astodrimer - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    G-103 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    GEN-003 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    genital herpes (virus like particle) vaccine - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    genital herpes vaccine - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    genital herpes vaccine - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    genital herpes vaccine - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    genital herpes vaccine - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    genital herpes vaccine - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    GV-2207 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    herpes simplex virus [type 1, 2] vaccine - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    herpes simplex virus 2 vaccine - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    herpes simplex virus 2 vaccine - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    herpes simplex virus 2 vaccine - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    herpes simplex virus 2 vaccine - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    herpes simplex virus 2 vaccine - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    HSV-529 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    NN-001 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    pritelivir - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Profavax HSV-1 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Profavax HSV-2 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecule for Genital Herpes - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Theravax HSV-1 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Theravax HSV-2 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    VCLHB-01 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    VCLHM-01 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    VTMX-004 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Genital Herpes - Dormant Projects

    Genital Herpes - Discontinued Products

    Genital Herpes - Product Development Milestones

    Featured News & Press Releases

    Mar 06, 2017: NanoBio Receives SBIR Grant For Genital Herpes Vaccine

    Jan 05, 2017: Genocea Announces Positive 6-Month Results from GEN-003 Phase 2b Clinical Trial

    Dec 14, 2016: Genocea R&D Day Highlighted Lead Program, GEN-003, for the Treatment of Genital Herpes and Introduced Immuno-Oncology Programs & Strategy

    Dec 01, 2016: AiCuris Announces Start of LipP 1: First Subject Enrolled in the Clinical Phase 2 Trial with Topical Pritelivir for the Treatment of recurrent Labial Herpes

    Oct 28, 2016: Genocea Presents New 12 month Data on Genital Herpes Immunotherapy GEN-003 at IDWeek 2016

    Oct 19, 2016: Admedus Announces Positive Unblinded HSV-2 Phase II Interim Data

    Sep 29, 2016: Genocea's Genital Herpes Immunotherapy GEN-003 Demonstrates Significant Reduction of Viral Shedding in Phase 2b Clinical Trial

    Jun 20, 2016: A novel therapy for genital herpes engages immune cells to provide significant patient benefits

    Jun 20, 2016: Vicals Phase 1/2 Trial Data Presented at ASM 2016 Shows Bivalent Vaccine Imparts Reduction in Genital Herpes Lesions Durable to 9 Months

    Jun 09, 2016: Genocea Showcases Potential of Genital Herpes Immunotherapy GEN-003 at ASM Microbe 2016

    Mar 31, 2016: Genital Herpes Immunotherapy GEN-003 Shows Sustained Reduction of Viral Shedding Rate, Durable Impact on Clinical Disease 12 Months Post-Dosing

    Mar 04, 2016: Interim HSV-2 Phase II clinical trial data encouraging

    Feb 03, 2016: Model helps decide drug dose for clinical testing

    Jan 29, 2016: Genocea Commences Dosing in Phase 2b Study for Genital Herpes Treatment, GEN-003

    Oct 07, 2015: Genocea Announces Positive Durability Data from 6-Month Analysis of Phase 2 Clinical Trial of Genital Herpes Immunotherapy GEN-003

    Appendix

    Methodology

    Coverage

    Secondary Research

    Primary Research

    Expert Panel Validation

    Contact Us

    Disclaimer

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

50184 | GMDHC9088IDB

Number of Pages

102

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 15% today! Genital Herpes - Epidemiology Forecast To 2023
DelveInsight “Genital Herpes - Epidemiology Forecast To 2023” provides an overview of the epidemiolo...
31 May 2017 by Delve Insight USD $2,338 (normally
USD $2,751)
More Info
SAVE 15% today! Genital Herpes-API Insights, 2017
The active pharmaceutical ingredients worldwide market is in continuous development from the recent ...
30 May 2017 by Delve Insight USD $1,063 (normally
USD $1,251)
More Info
SAVE 15% today! Genital Herpes - Market Insights, Epidemiology and Market Forecast-2023
Note*: This report requires 5-7 business days to complete.DelveInsight’s Genital Herpes - Market Ins...
30 May 2017 by Delve Insight USD $4,208 (normally
USD $4,951)
More Info
SAVE 15% today! Genital Herpes-Pipeline Insights, 2017
DelveInsight’s, “ Genital Herpes-Pipeline Insights, 2017”, report provides in depth insights on the ...
30 May 2017 by Delve Insight USD $1,063 (normally
USD $1,251)
More Info
SAVE 15% today! Genital Warts (Condylomata Acuminata)-Pipeline Insights, 2017
DelveInsight’s, “ Genital Warts (Condylomata Acuminata)-Pipeline Insights, 2017”, report provides in...
30 May 2017 by Delve Insight USD $1,063 (normally
USD $1,251)
More Info
SAVE 15% today! Genital Herpes-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
DelveInsight’s Report, “Genital Herpes-Global API Manufacturers, Marketed and Phase III Drugs Landsc...
30 May 2017 by Delve Insight USD $1,700 (normally
USD $2,000)
More Info
SAVE 15% today! Genital Warts (Condylomata Acuminata)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
DelveInsight’s Report, “Genital Warts (Condylomata Acuminata)-Global API Manufacturers, Marketed and...
30 May 2017 by Delve Insight USD $1,700 (normally
USD $2,000)
More Info
SAVE 15% today! Genital Warts (Condylomata Acuminata) Global Clinical Trials Review, H1, 2016
Genital Warts (Condylomata Acuminata) Global Clinical Trials Review, H1, 2016SummaryGlobalData's cli...
29 Feb 2016 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! Genital Herpes Global Clinical Trials Review, H1, 2016
Genital Herpes Global Clinical Trials Review, H1, 2016SummaryGlobalData's clinical trial report, “Ge...
29 Feb 2016 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! Genital Herpes Treatment Market: By Product type (Acyclovir, Famciclovir, Valacyclovir), By Distribution Channel (Hospital Pharmacies, General Pharmacies, Drug stores) & Geography -Forecast (2016-2021)
General herpes is categorised as a sexually transmitted disease/infection (STI) which is caused by h...
18 Feb 2016 by USD $4,463 (normally
USD $5,251)
More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Genital Herpes - Pipeline Review, H1 2017 [Report Updated: 22-03-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...